{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:44:20Z","timestamp":1792197860007,"version":"4.4.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The gut bacterial microbiota is increasingly recognized as a key modulator of colorectal cancer (CRC) initiation, progression and response to therapy. However, the mechanisms by which bacteria influence the response to anticancer drugs remain poorly understood. Here, we investigate the effects of microbiota-driven signaling on the tumor suppressor p53 and its impact on chemotherapy. We uncover a mechanism by which lipopolysaccharide (LPS) from\n                    <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                    and other Enterobacteria impairs p53 activity and promotes chemoresistance via paracrine signaling from the tumor microenvironment. While direct exposure to LPS did not alter the drug response of CRC cells, conditioned media from LPS-stimulated macrophages or fibroblasts suppressed p53 accumulation and attenuated the response to chemotherapeutic agents. Deep quantitative proteomics further revealed selective inhibition of a subset of p53 targets by inflammation. This same subset negatively correlated with inflammatory signature and immune infiltration in patients and was associated with improved survival following chemotherapy. Mechanistically, our data suggest that macrophage-derived extracellular vesicles contribute to p53 degradation in cancer cells. Overall, our findings reveal a microbiota-driven mechanism of p53 suppression via the microenvironment that contributes to chemoresistance, highlighting the impact of bacteria on tumor cell fate and therapeutic efficacy in CRC.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08756-4","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T02:28:09Z","timestamp":1776652089000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Klebsiella pneumoniae LPS drives stromal-mediated repression of p53 and colorectal cancer chemoresistance"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3564-8560","authenticated-orcid":false,"given":"Konstantinos","family":"Fragkoulis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"\u0141asut-Szyszka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1287-0906","authenticated-orcid":false,"given":"\u00c1kos","family":"V\u00e9gv\u00e1ri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diyoly","family":"Ayona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Ata","family":"Saei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-St\u00e9phanie","family":"Aschtgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3315-1935","authenticated-orcid":false,"given":"Sylvain","family":"Peuget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"8756_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA A Cancer J Clin"},{"key":"8756_CR2","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(24)00360-X","volume":"404","author":"C Eng","year":"2024","unstructured":"Eng C, Yoshino T, Ruiz-Garc\u00eda E, Mostafa N, Cann CG, O\u2019Brian B, et al. Colorectal cancer. Lancet. 2024;404:294\u2013310.","journal-title":"Lancet"},{"key":"8756_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/srep14554","volume":"5","author":"P Lehouritis","year":"2015","unstructured":"Lehouritis P, Cummins J, Stanton M, Murphy CT, McCarthy FO, Reid G, et al. Local bacteria affect the efficacy of chemotherapeutic drugs. Sci Rep. 2015;5:14554.","journal-title":"Sci Rep"},{"key":"8756_CR4","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1126\/science.aah5043","volume":"357","author":"LT Geller","year":"2017","unstructured":"Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017;357:1156\u201360.","journal-title":"Science"},{"key":"8756_CR5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3389\/fcimb.2017.00455","volume":"7","author":"H-L Li","year":"2017","unstructured":"Li H-L, Lu L, Wang X-S, Qin L-Y, Wang P, Qiu S-P, et al. Alteration of Gut microbiota and inflammatory cytokine\/chemokine profiles in 5-fluorouracil induced intestinal mucositis. Front Cell Infect Microbiol. 2017;7:455.","journal-title":"Front Cell Infect Microbiol"},{"key":"8756_CR6","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.cell.2017.07.008","volume":"170","author":"T Yu","year":"2017","unstructured":"Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170:548\u201363.e16.","journal-title":"Cell"},{"key":"8756_CR7","first-page":"1","volume":"38","author":"S Zhang","year":"2019","unstructured":"Zhang S, Yang Y, Weng W, Guo B, Cai G, Ma Y, et al. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer. J Exp Clin Cancer Res. 2019;38:1\u201313.","journal-title":"J Exp Clin Cancer Res"},{"key":"8756_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2333790","volume":"16","author":"N Wang","year":"2024","unstructured":"Wang N, Zhang L, Leng X-X, Xie Y-L, Kang Z-R, Zhao L-C, et al. Fusobacterium nucleatum induces chemoresistance in colorectal cancer by inhibiting pyroptosis via the Hippo pathway. Gut Microbes. 2024;16:2333790.","journal-title":"Gut Microbes"},{"key":"8756_CR9","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.ccell.2023.09.012","volume":"41","author":"LE Colbert","year":"2023","unstructured":"Colbert LE, El Alam MB, Wang R, Karpinets T, Lo D, Lynn EJ, et al. Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring. Cancer Cell. 2023;41:1945\u201362.e11.","journal-title":"Cancer Cell"},{"key":"8756_CR10","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/s41591-023-02453-x","volume":"29","author":"B Routy","year":"2023","unstructured":"Routy B, Lenehan JG, Miller WH, Jamal R, Messaoudene M, Daisley BA, et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nat Med. 2023;29:2121\u201332.","journal-title":"Nat Med"},{"key":"8756_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53347-6","volume":"15","author":"WS Lee","year":"2024","unstructured":"Lee WS, Lee SJ, Lee HJ, Yang H, Go E-J, Gansukh E, et al. Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer. Nat Commun. 2024;15:9092.","journal-title":"Nat Commun"},{"key":"8756_CR12","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41568-023-00594-2","volume":"23","author":"G El Tekle","year":"2023","unstructured":"El Tekle G, Garrett WS. Bacteria in cancer initiation, promotion and progression. Nat Rev Cancer. 2023;23:600\u201318.","journal-title":"Nat Rev Cancer"},{"key":"8756_CR13","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41586-022-05435-0","volume":"611","author":"JL Galeano Ni\u00f1o","year":"2022","unstructured":"Galeano Ni\u00f1o JL, Wu H, LaCourse KD, Kempchinsky AG, Baryiames A, Barber B, et al. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer. Nature. 2022;611:810\u20137.","journal-title":"Nature"},{"key":"8756_CR14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41568-023-00658-3","volume":"24","author":"S Peuget","year":"2024","unstructured":"Peuget S, Zhou X, Selivanova G. Translating p53-based therapies for cancer into the clinic. Nat Rev Cancer. 2024;24:192\u2013215.","journal-title":"Nat Rev Cancer"},{"key":"8756_CR15","doi-asserted-by":"publisher","first-page":"a026294","DOI":"10.1101\/cshperspect.a026294","volume":"6","author":"AI Robles","year":"2016","unstructured":"Robles AI, Jen J, Harris CC. Clinical outcomes of TP53 mutations in cancers. Cold Spring Harb Perspect Med. 2016;6:a026294.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"8756_CR16","first-page":"1649","volume":"2","author":"B Yang","year":"1996","unstructured":"Yang B, Eshleman JR, Berger NA, Markowitz SD. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res. 1996;2:1649\u201357.","journal-title":"Clin Cancer Res"},{"key":"8756_CR17","doi-asserted-by":"publisher","first-page":"a026260","DOI":"10.1101\/cshperspect.a026260","volume":"6","author":"J Ablain","year":"2015","unstructured":"Ablain J, Poirot B, Esnault C, Lehmann-Che J, de Th\u00e9 H. p53 as an effector or inhibitor of therapy response. Cold Spring Harb Perspect Med. 2015;6:a026260.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"8756_CR18","doi-asserted-by":"publisher","first-page":"E2543","DOI":"10.1073\/pnas.1205664109","volume":"109","author":"J Wei","year":"2012","unstructured":"Wei J, Noto J, Zaika E, Romero-Gallo J, Correa P, El-Rifai W, et al. Pathogenic bacterium Helicobacter pylori alters the expression profile of p53 protein isoforms and p53 response to cellular stresses. Proc Natl Acad Sci USA. 2012;109:E2543\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8756_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.chom.2012.01.013","volume":"11","author":"J Bergounioux","year":"2012","unstructured":"Bergounioux J, Elisee R, Prunier A-L, Donnadieu F, Sperandio B, Sansonetti P, et al. Calpain activation by the Shigella flexneri effector VirA regulates key steps in the formation and life of the bacterium\u2019s epithelial niche. Cell Host Microbe. 2012;11:240\u201352.","journal-title":"Cell Host Microbe"},{"key":"8756_CR20","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nrmicro3537","volume":"13","author":"C Siegl","year":"2015","unstructured":"Siegl C, Rudel T. Modulation of p53 during bacterial infections. Nat Rev Microbiol. 2015;13:741\u20138.","journal-title":"Nat Rev Microbiol"},{"key":"8756_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41586-020-2541-0","volume":"586","author":"E Kadosh","year":"2020","unstructured":"Kadosh E, Snir-Alkalay I, Venkatachalam A, May S, Lasry A, Elyada E, et al. The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic. Nature. 2020;586:133\u20138.","journal-title":"Nature"},{"key":"8756_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2024.106889","volume":"195","author":"Y-J Wu","year":"2024","unstructured":"Wu Y-J, Xiong J-F, Zhan C-N, Xu H. Gut microbiota alterations in colorectal adenoma-carcinoma sequence based on 16S rRNA gene sequencing: a systematic review and meta-analysis. Micro Pathog. 2024;195:106889.","journal-title":"Micro Pathog"},{"key":"8756_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65324-2","volume":"10","author":"GM de Waal","year":"2020","unstructured":"de Waal GM, de Villiers WJS, Forgan T, Roberts T, Pretorius E. Colorectal cancer is associated with increased circulating lipopolysaccharide, inflammation and hypercoagulability. Sci Rep. 2020;10:8777.","journal-title":"Sci Rep"},{"key":"8756_CR24","doi-asserted-by":"publisher","first-page":"e794","DOI":"10.1111\/j.1463-1318.2012.03174.x","volume":"14","author":"W-K Huang","year":"2012","unstructured":"Huang W-K, Chang JW-C, See L-C, Tu H-T, Chen J-S, Liaw C-C, et al. Higher rate of colorectal cancer among patients with pyogenic liver abscess with Klebsiella pneumoniae than those without: an 11-year follow-up study. Colorectal Dis. 2012;14:e794\u2013801.","journal-title":"Colorectal Dis"},{"key":"8756_CR25","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1038\/s41388-022-02238-5","volume":"41","author":"M-S Aschtgen","year":"2022","unstructured":"Aschtgen M-S, Fragkoulis K, Sanz G, Normark S, Selivanova G, Henriques-Normark B, et al. Enterobacteria impair host p53 tumor suppressor activity through mRNA destabilization. Oncogene. 2022;41:2173\u201386.","journal-title":"Oncogene"},{"key":"8756_CR26","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603\u20137.","journal-title":"Nature"},{"key":"8756_CR27","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/j.1432-1033.1989.tb14945.x","volume":"183","author":"A Weintraub","year":"1989","unstructured":"Weintraub A, Z\u00e4hringer U, Wollenweber HW, Seydel U, Rietschel ET. Structural characterization of the lipid A component of Bacteroides fragilis strain NCTC 9343 lipopolysaccharide. Eur J Biochem. 1989;183:425\u201331.","journal-title":"Eur J Biochem"},{"key":"8756_CR28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325.","journal-title":"Cell Syst"},{"key":"8756_CR29","doi-asserted-by":"publisher","first-page":"6070","DOI":"10.1093\/nar\/gkw523","volume":"44","author":"M Fischer","year":"2016","unstructured":"Fischer M, Grossmann P, Padi M, DeCaprio JA. Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F target gene analyses identifies cell cycle gene regulatory networks. Nucleic Acids Res. 2016;44:6070\u201386.","journal-title":"Nucleic Acids Res"},{"key":"8756_CR30","doi-asserted-by":"publisher","first-page":"14891","DOI":"10.1074\/jbc.270.25.14891","volume":"270","author":"C Tissot","year":"1995","unstructured":"Tissot C, Mechti N. Molecular cloning of a new interferon-induced factor that represses human immunodeficiency virus type 1 long terminal repeat expression. J Biol Chem. 1995;270:14891\u20138.","journal-title":"J Biol Chem"},{"key":"8756_CR31","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1038\/sj.onc.1207524","volume":"23","author":"S Obad","year":"2004","unstructured":"Obad S, Brunnstr\u00f6m H, Vallon-Christersson J, Borg A, Drott K, Gullberg U. Staf50 is a novel p53 target gene conferring reduced clonogenic growth of leukemic U-937 cells. Oncogene. 2004;23:4050\u20139.","journal-title":"Oncogene"},{"key":"8756_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ejca.2019.07.020","volume":"120","author":"C Truntzer","year":"2019","unstructured":"Truntzer C, Isambert N, Arnould L, Ladoire S, Ghiringhelli F. Prognostic value of transcriptomic determination of tumour-infiltrating lymphocytes in localised breast cancer. Eur J Cancer. 2019;120:97\u2013106.","journal-title":"Eur J Cancer"},{"key":"8756_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104018","volume":"186","author":"A Ottaiano","year":"2023","unstructured":"Ottaiano A, Santorsola M, Capuozzo M, Perri F, Circelli L, Cascella M, et al. The prognostic role of p53 mutations in metastatic colorectal cancer: a systematic review and meta-analysis. Crit Rev Oncol\/Hematol. 2023;186:104018.","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"8756_CR34","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41586-024-07769-3","volume":"633","author":"L Nunes","year":"2024","unstructured":"Nunes L, Li F, Wu M, Luo T, Hammarstr\u00f6m K, Torell E, et al. Prognostic genome and transcriptome signatures in colorectal cancers. Nature. 2024;633:137\u201346.","journal-title":"Nature"},{"key":"8756_CR35","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1158\/1078-0432.CCR-03-0362","volume":"10","author":"J Boyer","year":"2004","unstructured":"Boyer J, McLean EG, Aroori S, Wilson P, McCulla A, Carey PD, et al. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res. 2004;10:2158\u201367.","journal-title":"Clin Cancer Res"},{"key":"8756_CR36","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.3390\/cancers13102296","volume":"13","author":"M Michel","year":"2021","unstructured":"Michel M, Kaps L, Maderer A, Galle PR, Moehler M. The role of p53 dysfunction in colorectal cancer and its implications for therapy. Cancers. 2021;13:2296.","journal-title":"Cancers"},{"key":"8756_CR37","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1073\/pnas.012511599","volume":"99","author":"RA Mitchell","year":"2002","unstructured":"Mitchell RA, Liao H, Chesney J, Fingerle-Rowson G, Baugh J, David J, et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci USA. 2002;99:345\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8756_CR38","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1038\/onc.2014.1","volume":"33","author":"E Brighenti","year":"2014","unstructured":"Brighenti E, Calabrese C, Liguori G, Giannone FA, Trer\u00e8 D, Montanaro L, et al. Interleukin 6 downregulates p53 expression and activity by stimulating ribosome biogenesis: a new pathway connecting inflammation to cancer. Oncogene. 2014;33:4396\u2013406.","journal-title":"Oncogene"},{"key":"8756_CR39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41420-020-0272-5","volume":"6","author":"EH Cheteh","year":"2020","unstructured":"Cheteh EH, Sarne V, Ceder S, Bianchi J, Augsten M, Rundqvist H, et al. Interleukin-6 derived from cancer-associated fibroblasts attenuates the p53 response to doxorubicin in prostate cancer cells. Cell Death Discov. 2020;6:42.","journal-title":"Cell Death Discov"},{"key":"8756_CR40","doi-asserted-by":"publisher","first-page":"23663","DOI":"10.1073\/pnas.2008474117","volume":"117","author":"SM Moyer","year":"2020","unstructured":"Moyer SM, Wasylishen AR, Qi Y, Fowlkes N, Su X, Lozano G. p53 drives a transcriptional program that elicits a non-cell-autonomous response and alters cell state in vivo. Proc Natl Acad Sci USA. 2020;117:23663\u201373.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8756_CR41","first-page":"1149","volume":"58","author":"DJ Ahnen","year":"1998","unstructured":"Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA, et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res. 1998;58:1149\u201358.","journal-title":"Cancer Res"},{"key":"8756_CR42","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41586-023-06054-z","volume":"618","author":"F Mart\u00ednez-Jim\u00e9nez","year":"2023","unstructured":"Mart\u00ednez-Jim\u00e9nez F, Movasati A, Brunner SR, Nguyen L, Priestley P, Cuppen E, et al. Pan-cancer whole-genome comparison of primary and metastatic solid tumours. Nature. 2023;618:333\u201341.","journal-title":"Nature"},{"key":"8756_CR43","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.celrep.2019.07.001","volume":"28","author":"LA Donehower","year":"2019","unstructured":"Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, et al. Integrated analysis of TP53 gene and pathway alterations in the Cancer Genome Atlas. Cell Rep. 2019;28:1370\u201384.e5.","journal-title":"Cell Rep"},{"key":"8756_CR44","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S0140-6736(02)09969-5","volume":"360","author":"P Bertheau","year":"2002","unstructured":"Bertheau P, Plassa F, Espi\u00e9 M, Turpin E, de Roquancourt A, Marty M, et al. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet. 2002;360:852\u20134.","journal-title":"Lancet"},{"key":"8756_CR45","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.bcp.2011.12.026","volume":"83","author":"M Martinez-Rivera","year":"2012","unstructured":"Martinez-Rivera M, Siddik ZH. Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53. Biochem Pharmacol. 2012;83:1049\u201362.","journal-title":"Biochem Pharmacol"},{"key":"8756_CR46","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41416-024-02928-9","volume":"132","author":"SJ Cutty","year":"2025","unstructured":"Cutty SJ, Hughes FA, Ortega-Prieto P, Desai S, Thomas P, Fets LV, et al. Pro-survival roles for p21(Cip1\/Waf1) in non-small cell lung cancer. Br J Cancer. 2025;132:421\u201337.","journal-title":"Br J Cancer"},{"key":"8756_CR47","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.3390\/cancers15133399","volume":"15","author":"J Krishnaraj","year":"2023","unstructured":"Krishnaraj J, Yamamoto T, Ohki R. p53-dependent cytoprotective mechanisms behind resistance to chemo-radiotherapeutic agents used in cancer treatment. Cancers. 2023;15:3399.","journal-title":"Cancers"},{"key":"8756_CR48","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/s41379-019-0353-2","volume":"33","author":"DS Williams","year":"2020","unstructured":"Williams DS, Mouradov D, Browne C, Palmieri M, Elliott MJ, Nightingale R, et al. Overexpression of the TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer. Mod Pathol. 2020;33:483\u201395.","journal-title":"Mod Pathol"},{"key":"8756_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-020-00261-0","volume":"5","author":"J Dai","year":"2020","unstructured":"Dai J, Su Y, Zhong S, Cong L, Liu B, Yang J, et al. Exosomes: key players in cancer and potential therapeutic strategy. Sig Transduct Target Ther. 2020;5:1\u201310.","journal-title":"Sig Transduct Target Ther"},{"key":"8756_CR50","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrm.2017.125","volume":"19","author":"G van Niel","year":"2018","unstructured":"van Niel G, D\u2019Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19:213\u201328.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8756_CR51","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13046-019-1095-1","volume":"38","author":"X Zhu","year":"2019","unstructured":"Zhu X, Shen H, Yin X, Yang M, Wei H, Chen Q, et al. Macrophage-derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype. J Exp Clin Cancer Res. 2019;38:81.","journal-title":"J Exp Clin Cancer Res"},{"key":"8756_CR52","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s13046-019-1313-x","volume":"38","author":"Z Yin","year":"2019","unstructured":"Yin Z, Ma T, Huang B, Lin L, Zhou Y, Yan J, et al. Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-\u03b2 signaling pathway. J Exp Clin Cancer Res. 2019;38:310.","journal-title":"J Exp Clin Cancer Res"},{"key":"8756_CR53","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.cell.2005.04.017","volume":"121","author":"IGM Kolfschoten","year":"2005","unstructured":"Kolfschoten IGM, van Leeuwen B, Berns K, Mullenders J, Beijersbergen RL, Bernards R, et al. A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell. 2005;121:849\u201358.","journal-title":"Cell"},{"key":"8756_CR54","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1158\/0008-5472.CAN-19-2069","volume":"80","author":"S Peuget","year":"2020","unstructured":"Peuget S, Zhu J, Sanz G, Singh M, Gaetani M, Chen X, et al. Thermal proteome profiling identifies oxidative-dependent inhibition of the transcription of major oncogenes as a new therapeutic mechanism for select anticancer compounds. Cancer Res. 2020;80:1538\u201350.","journal-title":"Cancer Res"},{"key":"8756_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13582-8","volume":"10","author":"AA Saei","year":"2019","unstructured":"Saei AA, Beusch CM, Chernobrovkin A, Sabatier P, Zhang B, Tokat \u00dcG, et al. ProTargetMiner is a proteome signature library of anticancer molecules for functional discovery. Nat Commun. 2019;10:5715.","journal-title":"Nat Commun"},{"key":"8756_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202401502","volume":"11","author":"AA Saei","year":"2024","unstructured":"Saei AA, Lundin A, Lyu H, Gharibi H, Luo H, Teppo J, et al. Multifaceted proteome analysis at solubility, redox, and expression dimensions for target identification. Adv Sci. 2024;11:e2401502.","journal-title":"Adv Sci"},{"key":"8756_CR57","doi-asserted-by":"publisher","first-page":"W83","DOI":"10.1093\/nar\/gkw199","volume":"44","author":"J Reimand","year":"2016","unstructured":"Reimand J, Arak T, Adler P, Kolberg L, Reisberg S, Peterson H, et al. g: profiler-a web server for functional interpretation of gene lists (2016 update). Nucleic Acids Res. 2016;44:W83\u201389.","journal-title":"Nucleic Acids Res"},{"key":"8756_CR58","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498\u2013504.","journal-title":"Genome Res"},{"key":"8756_CR59","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41596-018-0103-9","volume":"14","author":"J Reimand","year":"2019","unstructured":"Reimand J, Isserlin R, Voisin V, Kucera M, Tannus-Lopes C, Rostamianfar A, et al. Pathway enrichment analysis and visualization of omics data using g: profiler, GSEA, Cytoscape and Enrichmentmap. Nat Protoc. 2019;14:482\u2013517.","journal-title":"Nat Protoc"},{"key":"8756_CR60","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8756_CR61","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"8756_CR62","doi-asserted-by":"crossref","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1.","DOI":"10.1126\/scisignal.2004088"},{"key":"8756_CR63","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462:108\u201312.","journal-title":"Nature"},{"key":"8756_CR64","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nbt.2839","volume":"32","author":"JA Vizca\u00edno","year":"2014","unstructured":"Vizca\u00edno JA, Deutsch EW, Wang R, Csordas A, Reisinger F, R\u00edos D, et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat Biotechnol. 2014;32:223\u20136.","journal-title":"Nat Biotechnol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08756-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08756-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08756-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T04:02:25Z","timestamp":1776657745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08756-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8756"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08756-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with relevant guidelines and regulations. This study did not involve human participants or animals directly. The analyses were conducted using established cell lines and publicly available, de-identified data from The Cancer Genome Atlas (TCGA), which comply with ethical standards and data usage policies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"ETHICS APPROVAL AND CONSENT TO PARTICIPATE"}}],"article-number":"395"}}